There is accumulating evidence that sulfated lipids, sulfated oligosaccharides and other sulfated compounds are reactive with selectins in a manner that interferes with selectin interactions with their natural ligands. In the report we describe the ability of sulfated lipids (sulfatides and gangliosides) and multimeric forms of sulfated sialic acid to block binding of P-and E-selectin-Ig to neutrophils. The in vivo ability of these compounds to block lung injury in rats following i.v. infusion of purified cobra venom factor (CVF), which induces injury that is L-and P-selectin dependent, was also determined as well as effects on recruitment of neutrophils, as measured by lung myeloperoxidase. There was a significant correlation between the ability of sulfated lipids and sialyl compounds to interfere in vitro with P-selectin-Ig binding to neutrophils and to protect against P-selectin-dependent acute lung injury induced by CVF. The biological effects of these sulfated compounds were also associated with diminished accumulation of neutrophils. The protective effects of these compounds may be linked to their ability to interfere with P-selectin binding to counter-receptors on neutrophils.
Introduction
Sulfated lipids, sulfated oligosaccharides and sulfated glycans may interfere with selectin binding interactions with their 'counter-receptors' on endothelial cells or on leukocytes (reviewed in [1] [2] [3] [4] . Lymphocyte binding to high endothelial venules of lymph nodes occurs via lymphocyte surface content of L-selectin, which interacts with sulfated, fucosylated and sialylated glycoproteins, glyCAM-1 and CD34 on endothelial cells (5) (6) (7) . Among the selectin-reactive compounds are sialylated and non-sialylated fucosylated lactosamines, sulfatides, sulfated glucuronyl lipids, and sulfated glycans, most of which bind to L-and P-selectins and less well to Eselectin (1) (2) (3) (4) . Based on extensive work with P-selectin and employing site-directed mutagenesis, it appears that Pselectin binds to surfaces of myeloid cells or to sulfatides via an overlapping but non-identical series of amino acid residues Correspondence to: P. A. Ward
Transmitting editor: K. Sugamura Received 10 October 1997, accepted 21 November 1997 present in the P-selectin molecule proximal to the calcium binding site (8, 9) . It has also been demonstrated that sulfatides can interfere with binding of P-selectin to neutrophils (10) . We have recently demonstrated that naturally occurring sulfatide (from bovine brain) and synthetic sulfatides have significant, protective effects in acute lung injury which occurs after i.v. infusion of purified cobra venom factor (CVF) into rats (11) . This model is known to be L-and P-(but not E-) selectin dependent (12) (13) (14) . The protective effects of sulfatides were associated with reduced neutrophil accumulation in lung. These studies suggested that the position of the sulfate group in the pyranosyl ring of Gal may be important (11) . In the following series of studies we have evaluated the ability of sulfated lipids (sulfatides and sulfated gangliosides), sulfated monomeric, dimeric and polysialyl compounds to block in vitro binding of P-and E-selectin-Ig to neutrophils. In parallel, we have evaluated the ability of these compounds to interfere with CVF-induced lung injury in rats. In general, there appears to be a correlation between the ability of these sulfated compounds to block in vitro binding of P-selectin to neutrophils and their ability to block in vivo selectin-dependent lung injury.
Methods

Analysis of selectin binding to neutrophils
Binding was analyzed by flow cytometric measurement of the inhibition of binding of P-and E-selectin-Ig by sulfated compounds. Briefly, neutrophils (2.5ϫ10 5 ) isolated from human blood by Ficoll/dextran sedimentation methodology were incubated with varying concentrations of sulfated compounds and P-or E-selectin-Ig (4 µg/ml) for 30 min on ice. Cells were washed with DPBS and bound P-or E-selectinIg was detected with phycoerythrin-conjugated antibody to human IgM (Sigma, St Louis, MO). Cell suspensions were subsequently fixed in 2% paraformaldehyde solution. Human blood neutrophil populations (identified by forward versus right angle light scatter characteristics) were measured on a FACScan (Becton Dickinson, San Jose, CA) in which 100,000 cells per gated determination were counted. The extent of fluorescence intensity (mean channel fluorescence) was analyzed using PC-Lysys software. Human blood neutrophils were used because it was not possible to obtain sufficient numbers of purified rat blood neutrophils for the studies, and because rat peritoneal neutrophils, while abundant, shed selectin ligands due to their state of activation and were therefore considered inappropriate for binding studies. Not surprisingly, in vitro studies revealed good selectin chimeric binding to human neutrophils and poor binding to rat peritoneal neutrophils.
Selectin chimeric compounds
Mouse E-and P-selectin-IgM chimeras were constructed from mouse E-and P-selectin cDNAs. PCR-amplified fragments corresponding to their lectin, epidermal growth factor and two complement repeat domains were linked to DNA sequence encoding the CH2, CH3 and CH4 domains of human IgM in a mammalian expression vector. Selectin-IgM chimeras were collected from the media of COS cells transfected with the E-or P-selectin chimera expression vectors. Chimeras were biotinylated after purification by antibody-affinity chromatography (goat anti-human IgM).
FACS analysis (two-color) was performed with phycoerythrin-labeled mAb and either biotinylated selectin-IgM chimeras detected with FITC-conjugated avidin (25 µg/ml; PharMingen, San Diego, CA) or COS cell media-derived chimeras detected with FITC-conjugated goat anti-human IgM (20 µg/ml; Sigma). Alternatively, the four phycoerythrinlabeled mAb were used with FITC-conjugated reagents.
Sulfated glycolipids and gangliosides
Native sulfated were isolated as follows: fresh bovine brain gray matter (1 kg) was homogenized with 5 volumes of acetone and filtered. Dried residue was extracted with 5 volumes of chloroform:methanol (2:1, v/v) and then 1:1 (v/v). Total lipid extract was evaporated to dryness and extracted with 3 volumes of acetone. The residue was treated with 3 volumes of diethylether to remove glycerophospholipids, and then treated with 0.5N NaOH:methanol at 37°C for 3 h, dialyzed against distilled water and lyophilized. Crude alkali stable lipid fraction was subjected to Folch's partition. The lower phase was subjected to Q-Sepharose column chromatography (15) . Sulfatide fraction was eluted with a linear gradient (0.4 M) of sodium acetate in chloroform:methanol:water (30:60:8, v/v/v), dialyzed against distilled water, lyophilized and purified with Iatrobeads column chromatography as described (15 and SO 3 -3-Galβ1-4(Fucα1-3)GIcβ1-B30 were reported as described (16) (17) (18) . Bovine brain gangliosides and their sulfated compounds were prepared as described previously (19) .
Sulfation of sialyl compounds
For sulfation of monomeric and dimeric N-acetylneuraminic acid (NANA) with sulfur trioxide trimethylamine complex. Each sample of monomeric and dimeric NANA (1 mol; Nacalai Tesque, Location?, Japan) was sulfated at room temperature for 20 h using sulfur trioxide trimethylamine complex (6 mol; Aldrich, St Louis, MO) in N,N-dimethylformamide (DMF), (Merck, Rathway, NJ). The reaction mixture was neutralized with 1 M sodium hydrogen carbonate and dialyzed against distilled water. The dialyzed solution was passed through a column of Amberlite IR-120B (Na ϩ form). The effluent and washings were combined, concentrated in vacuo and lyophilized. The sulfated monomeric and dimeric NANAs were named NANA-S2, (NANA) 2 -S3 and (NANA) 2 -S7 respectively.
Furthermore, each sample of NANA-S2 and (NANA) 2 -S3 was applied to a column of Amberlite IRA-93ZU (Cl form) and eluted using sodium chloride. The eluate with 2 M sodium chloride was dialyzed against distilled water, concentrated in vacuo and lyophilized. The purified sialyl compounds were named NANA-S3 and (NANA) 2 -S4 respectively.
For sulfation of monomeric and dimeric NANA with sulfur trioxide pyridine complex, each sample of monomeric and dimeric NANA was sulfated at -20°C for 20 h using 10 mol sulfur trioxide pyridine complex (Aldrich) and 1 mol 4-dimethylaminopyridine (Merck) in DMF. After that the following steps were performed according to the above-mentioned methods. The sulfated monomeric and dimeric NANAs were named NANA-S4, NANA-S6, NANA-S7, (NANA) 2 -S2 and (NANA) 2 -S5 respectively.
Each sample of NANA-S4 and (NANA) 2 -S5 was further purified by Amberlite IRA-93ZU (C1 form) column chromatography as described. The purified sialyl compounds were named NANA-S5 and (NANA) 2 -S6 respectively.
For sulfation of oligomeric NANA and colominic acid with the sulfur trioxide pyridine complex, each sample of oligomeric NANA from trimeric to hexameric NANA (Nacalai Tesque) was sulfated at -20°C for 20 h using 10 mol sulfur trioxide pyridine complex and 1 mol 4-dimethylaminopeptine in DMF. After that, the next procedures were according to methods mentioned above. The sulfated oligomeric NANAs were termed (NANA) 3 SO 3 (NANA) 4 SO 3 , (NANA) 5 SO 3 and (NAN-A) 6 SO 3 respectively.
Colominic acid (Nacalai Tesque), a homopolymer of NANA with~50 molecules of NANA, was sulfated with sulfur trioxide pyridine complex and 4-dimethylaminopyridine in DMF. The reactions were carried out at -20 and 30°C for 24 h respectively. After that, the next procedures were according to methods described above. The sulfated colominic acids were termed (NANA) 50 (SO 3 ) 50 and (NANA) 50 (SO 3 ) 100 respectively.
Determination of sulfur content
The sulfur contents of the sulfated sialyl compounds were determined with sulfuric acid as the standard (18) .
Animal model
Acute lung injury in young adult (300 g) specific pathogenfree Long Evans rats was induced by i.v. infusion of 4 U purified CVF, as described elsewhere (11) . Lung damage was measured 30 min after i.v. injection of CVF with 3 µCi [ 125 I]BSA. Lung radioactivity in saline-flushed lungs was measured and compared with the amount of radioactivity present in 1.0 ml blood obtained from the inferior vena cava at the time of killing (at 30 min). This permitted calculation of permeability and hemorrhage indices. In turn, protective effects of various interventional agents were determined. Neutrophil accumulation in lung, as reflected by tissue content of myeloperoxidase (MPO), was measured by the decomposition of H 2 O 2 in the presence of o-dianisidine (11) .
Statistical methods
One-way and two-way analysis of variance was determined. As appropriate, Student's t-test was used for additional comparisons. In some selected studies, the Pearson product moment correlation test or the Spearman analysis of correlation was also employed.
Results
Dose-response inhibition of selectin binding to neutrophils by sulfated compounds Figure 1 shows typical dose-response relationships between the ability of sulfated compounds to inhibit binding of P-or E-selectin-Ig to human neutrophils in the presence of a fixed amount of selectin (4 µg/ml) and increasing concentrations of sulfated compounds. Human neutrophils were used for these binding studies for the reasons described above. Binding of selectin-Ig to neutrophils was determined by flow cytometric analysis (employing a phycoerythrin-conjugated antibody to the Fc region of human IgM). In Fig. 1(A) , increasing concentrations of synthetic monosulfated sulfatide, I 4 SO 3 Gal B30 (structure described elsewhere, 11), revealed a dose-dependent inhibition of binding of P-selectin-Ig to neutrophils and poor inhibition of binding of E-selectin-Ig to neutrophils. The IC 50 for sulfatide-induced blocking of Pselectin-Ig binding was 0.93 µM, whereas inhibition of Eselectin-Ig binding never exceeded 18%. In the case of I 3,4,6 SO 3 Gal B30 (Fig. 1B) , there was a dose-dependent inhibition in the binding of both P-and E-selectin-Ig to neutrophils (Fig. 1B) . In additional studies the calculated IC 50 values for I 3,4,6 SO 3 Gal B30-induced inhibition in binding of P-and E-selectin-Ig were 0.70 and 1.93 µM respectively (Table 1) . When sulfated tetraneuraminic acid [(NANA) 4 SO 3 ] was used (Fig. 1C) , the IC 50 value for inhibition of P-selectinIg binding to neutrophils was 4.45 µM, while no significant inhibition in binding of E-selectin-Ig to neutrophils was found. For all compounds described in Tables 1-3 , similar doseresponse profiles were determined.
In vitro inhibitory activities of sulfated lipids on selectin binding to neutrophils
The first comprehensive series of experiments involved the use of naturally occurring bovine brain sulfatide (I 3 SO 3 GalCer) or synthetic sulfatides (e.g. I 3 SO 3 Gal B30) in which Cer was replaced with a long chain branched alcohol (B30). The desulfated sulfatide (GalCer) served as a negative control. In addition, sulfated and desulfated gangliosides were also evaluated. The ability of these compounds to block binding of either P-or E-selectin-Ig to neutrophils was determined. Dose-response experiments were carried out in order to Sulfated ganglioside was also highly active in blocking of P-selectin-Ig binding to neutrophils and demonstrated much less activity in blocking the binding of E-selectin-Ig to neutrophils. In the case of gangliosides, desulfated gangliosides had very little activity when compared to the effects of sulfated gangliosides. Sulfated compounds consisting of N-stearoyl myristylamide or di-myristyl propanediol revealed rather poor interference in binding of either P-or E-selectin-Ig to neutrophils. Finally, the non-sialylated but fucosylated and sulfated compound, SO 3 -3-Gal-β1-4(Fucα1-3)Glcβ1-B30, had no measurable inhibitory effect on selectin-Ig binding to neutrophils.
In vivo protective effects of sulfated lipids on CVF-induced lung injury
In parallel experiments, rats were infused i.v. with 1.0 mg GalCer or various sulfatides, sulfated or desulfatide gangliosides, or other sulfated compounds. The protective effects on CVF-induced acute lung injury were measured as a function of permeability change (leakage of [ 125 I]albumin) as well as neutrophil accumulation (as determined by lung MPO content). The results are also shown in Table 1 . GalCer had no ϾϾ GalCer. Virtually identical patterns were found when MPO was used as the endpoint. Sulfated ganglioside was also protective, whereas the desulfated ganglioside was not. In contrast to the poor blocking effects on selectin binding to neutrophils by sulfated N-stearoyl myristylamide or sulfated di-myristyl propanediol compounds, both compounds had significant protective effects on permeability usage and MPO build-up (Table 1 ). In general, there was a close correlation between reductions in permeability and reductions in MPO content in lung. Statistical comparisons were performed to evaluate inhibition of in vitro binding (of either P-or E-selectin-Ig) to neutrophils with the in vivo protective effects of these compounds, using permeability change as the parameter of injury. Using the Pearson product moment correlation test, when inhibitory effects of sulfated compounds on binding of Pselectin-Ig to neutrophils were compared to protective effects in vivo (reduction in permeability) of the same compounds, the r value was 0.78 (P ϭ 0.013). When inhibition of E-selectin binding to neutrophils was compared to lung protective effects of the same compounds, r ϭ 0.71 (P ϭ 0.031). Thus, there appears to be a correlation between blocking effects of sulfated lipids on in vitro binding of selectins to neutrophils and effects of the same compounds in protection against CVF-induced lung injury. It is interesting to note that sulfated lipids blocked binding of both selectins to neutrophils, even though in the CVF model P-but not E-selectin appears to be involved in development of this form of lung injury (11) (12) (13) (14) . To what extent any of these protective effects might be related to the ability of sulfated lipids to block in vivo interactions of L-selectin with naturally occurring 'counter-receptors' on endothelial cells is unknown.
In vitro and in vivo blocking activities of sulfated monomeric and dimeric forms of NANA In these experiments we employed monomeric and dimeric forms of NANA containing sulfate groups that had been added to NANA by the use of various sulfating agents (sulfated trimethylamine or sulfated pyridine complex). For all sulfated forms of NANA, the molar ratio of sulfate present in NANA varied from 1.1 to 1.6 (Table 2 ). In vitro, these compounds revealed very limited inhibitory activity for blocking the binding of P-selectin-Ig to neutrophils; no inhibitory activity was found in binding of E-selectin-Ig to neutrophils (Table 2) . NANA-S2, NANA-S4, (NANA) 2 -S3 and (NANA) 2 -S5 revealed some modest inhibitory activity for P-selectin binding to neutrophils, while the other forms of NANA were without effect.
When six of these compounds were tested in vivo, no statistically significant reductions in lung vascular permeability or reduction in lung MPO content were found. On the basis of the high concentrations of sulfated NANA compounds required to block binding of P-selectin to neutrophils (in contrast to the concentration of sulfatides that blocked binding), it was not surprising that no significant protective effects of these NANA compounds could be demonstrated in the model of lung injury employed. As will be shown below, multimeric sulfated forms of NANA had significant levels of biological activity under the same text conditions.
In vitro and in vivo blocking activities of polymeric sialyl compounds
In this series of experiments, multimeric forms of sulfated NANA were used, varying from dimeric to hexameric forms and also including colominic acid (a homopolymer of NANA with~50 molecules of NANA). Some versions of colominic acid contained one or two sulfated groups per NANA. The data for the in vitro studies are shown in Table 3 . Consistent with the data in Table 2 , dimeric forms of NANA, whether or not sulfated, had no inhibitory effects on vitro binding of Por E-selectin-Ig to neutrophils. However, the more extended polymers of NANA showed blocking activity for P-selectin uptake by neutrophils. The descending rank order of these compounds for in vitro blocking of P-selectin-Ig to neutrophils was: (NANA) 50 (SO 3 ) 100 ജ (NANA) 50 (SO 3 ) 50 Ͼ (NANA) 6 SO 3 Ͼ (NANA) 5 SO 3 ϭ (NANA) 50 Ͼ (NANA) 4 SO 3 Ͼ (NANA) 3 SO 3 . With respect to in vitro blockade of binding of E-selectin-Ig to neutrophils, with the exception of (NANA) 5 SO 3 , which had a low level of activity (IC 50 ϭ 418 µM), none of the compounds was active.
When in vivo protective effects of these compounds were evaluated in the lung injury model, the monosulfated tetra and penta forms of NANA had protective effects (ranging from 37 to 58% reduction in albumin leak into lung), as did the sulfated forms of colominic acid (causing 42-52% protection from albumin leak into lung, Table 3 ). None of the other forms of NANA had any protective effects. Protective effects of the NANA compounds were paralleled very closely by reductions in build-up of lung MPO ( Table 3 ). The descending rank order for in vivo protective effects of these multimeric compounds was: (NANA) 4 SO 3 ϭ (NANA) 50 (SO 3 ) 50 ജ (NANA) 50 (SO 3 ) 100 ϭ (NANA) 5 SO 3 Ͼ (NANA) 6 SO 3 ϾϾ all other NANA compounds. Using the Spearman analysis of correlation, when the blocking effects of NANA compounds on P-selecting binding to neutrophils were compared to in vivo lung protective effects, r ϭ 0.884 (P Ͻ 0.007). When blocking effects on E-selectin binding to neutrophils were correlated with in vivo protective effects in lung, r ϭ 0.436 (P ϭ 0.250). Thus, certain of the sulfated polymeric NANA compounds block not only binding of P-selectin-Ig to neutrophils but also protect against CVF-induced acute lung injury in a manner that is related to reduced accumulation in lung of MPO.
Discussion
Naturally occurring or synthetic sulfatides have previously been shown to be reactive with L-and P-selectin-Ig as determined by a variety of techniques (9, 10, 20) . The data in the current report are consistent with other studies which suggest that binding interactions between P-selectin and sulfated lipids are more effective than the binding interactions between E-selectin-Ig and sulfated lipids (3, 4) . It has been shown that L-selectin-Ig shows good binding both to sulfatide and to sialyl Lewis x ; in contrast, P-selectin-Ig shows greater binding to sulfatide as compared to binding to sialyl Lewis x ; finally, E-selectin-Ig shows substantial binding to sialyl Lewis x and less binding to sulfatide (reviewed in 4). Such data seem to have some similarity to results obtained in the current study in which sulfated compounds were examined for their ability to block binding of P-or E-selectin-Ig to neutrophils. In the case of sulfatides, interference with selectin binding to neutrophils was not demonstrably different when P-and Eselectin-Ig binding was compared (Table 1) . However, in the case of multimeric sulfated forms of sialic acid, these compounds were clearly more effective in blocking P-selectinIg binding to neutrophils when compared to very little blocking of the binding of E-selectin-Ig to neutrophils (Table 3 ). In the case of binding of P-and E-selectin-Ig to neutrophils in the presence or absence of sulfated compounds, it seems likely that these binding interactions involve selectin binding to Pselectin glycolipid ligand-1 (PSGL-1) or E-selectin ligand-1 (ESL-1), or both (reviewed in 4).
The data in this report indicate a correlation between inhibitory effects of sulfated compounds for binding of Pselectin-Ig (and in some cases also E-selectin-Ig) to neutrophils and the ability of these compounds to demonstrate protective effects (as determined by albumin leak into lung) in the L-and P-selectin-dependent model of acute lung injury following i.v. infusion of CVF. This correlation holds in the case of sulfated lipids (Table 1) as well as in the case of sulfated polymeric forms of NANA (Table 3) . While the correlations are not precise, they are, nevertheless, statistically significant, with r Ͼ 0.70. There is also a significant correlation between the protective effects of sulfated compounds in the lung and their attendant ability to reduce neutrophil accumulation in lung (as measured by MPO content) (Tables 1 and 3 ). Similar findings have been described when blocking antibodies to L-or P-selectin have been employed in this model of lung injury (12, 13) or when L-or P-selectin-Ig has been infused i.v. (14) .
It has been reported that sulfatides (in appropriate concentrations) can induce signal transduction events in leukocytes (leading to increased intracellular calcium and Ins 1,4,5 P 3 ), together with release of cytokines (20) . It has also been shown that activated neutrophils secrete sulfatide in a rapid manner and that the amounts secreted are sufficient to interfere with selectin (depending on the neutrophils), suggesting that sulfatide may act as an anti-adhesive regulator in cell adhesion (22) . However, leukocyte activation did not occur when sulfatides were used in vivo in rats (under the same experimental conditions described in Tables 1-3) , since blood neutrophils failed to show increased surface expression of either CD11b or CD18, both being sensitive markers of neutrophil activation (11) . In addition, a reliable indicator of in vivo neutrophil activation, neutropenia, which occurs after infusion of chemotactically active factors for neutrophils (22) , was not found in vivo following sulfatide infusion (11) . The concentrations of sulfatide required in vitro to activate leukocytes substantially exceeded the calculated concentrations of sulfatide present in rat blood after i.v. infusion. Accordingly, it does not seem likely that the in vivo protective effects of sulfated compounds can be explained by neutrophil activation (and their subsequent deactivation) in vivo. Nevertheless, it is possible that leukocyte release of sulfatide may regulate the inflammatory response by interfering with selectin-dependent adhesive interactions. It remains to be determined in what manner sulfatides interfere with the binding interactions between neutrophils and selectins.
We note that absence of inhibitory activity with 3Ј-sulfo Lewis x-B30 is in apparent conflict with observations of others who have described that 3Ј-sulfo Lewis x-type molecules can bind to selectins (23, 24) . This apparent discrepancy may be accounted for by the fact that our in vitro experiments have not examined L-selectin-dependent binding interactions, by the fact that our assays are significantly different from assays used by others (e.g. cells in suspension versus solid phase ligands), and by the fact that the compounds examined by us and by others have subtle structural differences that may affect their selectin ligand binding properties.
